Sudhir Sahasrabudhe
Director/Board Member at Utah State University Foundation
Profile
Sudhir Sahasrabudhe is currently an Associate Member at Massachusetts Institute of Technology and a Trustee at Utah State University Foundation.
He previously worked as Acting CEO & Chief Scientific Officer at Prolexys Pharmaceuticals, Inc., Senior Director-Biotechnology at Aventis Pharmaceuticals, Inc., and Executive Vice President-Research & Development at Myriad Genetics, Inc. Dr. Sahasrabudhe received his undergraduate and graduate degrees from the University of Baroda and his doctorate in 1987 from the same institution.
Sudhir Sahasrabudhe active positions
| Companies | Position | Start |
|---|---|---|
| Utah State University Foundation | Director/Board Member | - |
| Massachusetts Institute of Technology | Corporate Officer/Principal | - |
Former positions of Sudhir Sahasrabudhe
| Companies | Position | End |
|---|---|---|
| MYRIAD GENETICS, INC. | Chief Tech/Sci/R&D Officer | - |
Aventis Pharmaceuticals, Inc.
 Aventis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aventis Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The company was founded in 1950 and is headquartered in Bridgewater, NJ. | Chief Tech/Sci/R&D Officer | - |
Prolexys Pharmaceuticals, Inc.
 Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | Chief Executive Officer | - |
Training of Sudhir Sahasrabudhe
| University of Baroda | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| MYRIAD GENETICS, INC. | Health Technology |
| Private companies | 3 |
|---|---|
Aventis Pharmaceuticals, Inc.
Aventis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aventis Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The company was founded in 1950 and is headquartered in Bridgewater, NJ. | Health Technology |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | Health Technology |
| Utah State University Foundation |
- Stock Market
- Insiders
- Sudhir Sahasrabudhe
